Cargando…

Cell Therapy in Heart Failure with Preserved Ejection Fraction

Heart failure with preserved ejection fraction (HFpEF) is the most common cause of hospitalisation for heart failure. However, only limited effective treatments are available. Recent evidence suggests that HFpEF may result from a systemic proinflammatory state, microvascular endothelial inflammation...

Descripción completa

Detalles Bibliográficos
Autores principales:	Frljak, Sabina, Poglajen, Gregor, Vrtovec, Bojan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Radcliffe Cardiology 2022
Materias:	Therapy
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8977993/ https://www.ncbi.nlm.nih.gov/pubmed/35399548 http://dx.doi.org/10.15420/cfr.2021.21

Ejemplares similares

A pilot clinical trial of cell therapy in heart failure with preserved ejection fraction
por: Vrtovec, Bojan, et al.
Publicado: (2022)

Long-Term Effects of Angiotensin Receptor–Neprilysin Inhibitors on Myocardial Function in Chronic Heart Failure Patients with Reduced Ejection Fraction
por: Poglajen, Gregor, et al.
Publicado: (2020)

Transendocardial CD34+ Cell Therapy does not Increase the Risk of Ventricular Arrhythmias in Patients with Chronic Heart Failure
por: Poglajen, Gregor, et al.
Publicado: (2019)

Favorable Response to CD34+ Cell Therapy Is Associated with a Decrease of Galectin-3 Levels in Patients with Chronic Heart Failure
por: Poglajen, Gregor, et al.
Publicado: (2019)

Transendocardial CD34(+) Cell Therapy Improves Local Mechanical Dyssynchrony in Patients With Nonischemic Dilated Cardiomyopathy
por: Žorž, Neža, et al.
Publicado: (2022)

CD34(+) Cell Transplantation Improves Right Ventricular Function in Patients with Nonischemic Dilated Cardiomyopathy
por: Frljak, Sabina, et al.
Publicado: (2018)

Medical Treatment of Heart Failure with Reduced Ejection Fraction in the Elderly
por: Milinković, Ivan, et al.
Publicado: (2022)

Contemporary Challenges of Regenerative Therapy in Patients with Ischemic and Non-Ischemic Heart Failure
por: Banovic, Marko, et al.
Publicado: (2022)

Sacubitril/valsartan and loop diuretic requirement in heart failure with preserved ejection fraction in the PARAGON‐HF trial
por: Chatur, Safia, et al.
Publicado: (2022)

Management of Type 2 Diabetes in Stage C Heart Failure with Reduced Ejection Fraction
por: Agarwalla, Anjali, et al.
Publicado: (2022)

Stem Cell Therapy in Patients with Chronic Nonischemic Heart Failure
por: Poglajen, Gregor, et al.
Publicado: (2018)

Transendocardial CD34(+) Cell Transplantation in Noncompaction Cardiomyopathy: First-in-Man Case Study
por: Cerar, Andraz, et al.
Publicado: (2018)

Rationale for and Practical Use of Sacubitril/Valsartan in the Patient’s Journey with Heart Failure and Reduced Ejection Fraction
por: Gori, Mauro, et al.
Publicado: (2021)

Effects of Transendocardial CD34(+) Cell Transplantation on Diastolic Parameters in Patients with Nonischemic Dilated Cardiomyopathy
por: Bervar, Mojca, et al.
Publicado: (2017)

Cell Therapy for Heart Failure With Preserved Ejection Fraction
por: Borlaug, Barry A., et al.
Publicado: (2016)

TNF-α Predicts Endothelial Function and Number of CD34(+) Cells after Stimulation with G-CSF in Patients with Advanced Heart Failure
por: Ugovšek, Sabina, et al.
Publicado: (2022)

Weight change and clinical outcomes in heart failure with reduced ejection fraction: insights from EMPEROR‐Reduced
por: Anker, Stefan D., et al.
Publicado: (2022)

Dementia‐related adverse events in PARADIGM‐HF and other trials in heart failure with reduced ejection fraction
por: Cannon, Jane A., et al.
Publicado: (2016)

Heart failure with preserved ejection fraction
por: Rigolli, Marzia, et al.
Publicado: (2013)

Heart failure with preserved ejection fraction
por: ElGuindy, Ahmed, et al.
Publicado: (2012)

Medical Therapy for Heart Failure with Preserved Ejection Fraction
por: Varnado, Sara, et al.
Publicado: (2022)

Biomarkers in Heart Failure with Preserved Ejection Fraction
por: Bayes-Genis, Antoni, et al.
Publicado: (2022)

Comorbidities in heart failure with preserved ejection fraction
por: Deichl, Andrea, et al.
Publicado: (2022)

Biomarkers in heart failure with preserved ejection fraction
por: Meijers, W. C., et al.
Publicado: (2016)

Management of heart failure with preserved ejection fraction
por: Gard, Emma, et al.
Publicado: (2020)

Managing heart failure with preserved ejection fraction
por: Davidson, Alexander, et al.
Publicado: (2020)

Left atrial ejection fraction and outcomes in heart failure with preserved ejection fraction
por: Kanagala, Prathap, et al.
Publicado: (2019)

Effects of Sacubitril/Valsartan on Exercise Capacity in Patients with Heart Failure with Reduced Ejection Fraction and the Role of Percentage of Delayed Enhancement Measured by Cardiac Magnetic Resonance in Predicting Therapeutic Response: A Multicentre Study
por: Nugara, Cinzia, et al.
Publicado: (2023)

Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: GALACTIC‐HF baseline characteristics and comparison with contemporary clinical trials
por: Teerlink, John R., et al.
Publicado: (2020)

Endocrine disorders after heart transplantation: national cohort study
por: Rakusa, Matej, et al.
Publicado: (2020)

Cost‐effectiveness of dapagliflozin as a treatment for heart failure with reduced ejection fraction: a multinational health‐economic analysis of DAPA‐HF
por: McEwan, Phil, et al.
Publicado: (2020)

Prognostic Value of Anxiety Between Heart Failure With Reduced Ejection Fraction and Heart Failure With Preserved Ejection Fraction
por: Lin, Tin‐Kwang, et al.
Publicado: (2019)

Right Heart Phenotype in Heart Failure With Preserved Ejection Fraction
por: Guazzi, Marco, et al.
Publicado: (2021)

Management strategies in heart failure with preserved ejection fraction
por: Wintrich, Jan, et al.
Publicado: (2022)

Contractile Reserve in Heart Failure with Preserved Ejection Fraction
por: Di Lisi, Daniela, et al.
Publicado: (2022)

Epigenetic remodeling in heart failure with preserved ejection fraction
por: Ambrosini, Samuele, et al.
Publicado: (2022)

Reshaping Treatment of Heart Failure with Preserved Ejection Fraction
por: Karamichalakis, Nikolaos, et al.
Publicado: (2022)

Metabolomic Fingerprint of Heart Failure with Preserved Ejection Fraction
por: Zordoky, Beshay N., et al.
Publicado: (2015)

Clinical Phenotypes in Heart Failure With Preserved Ejection Fraction
por: Samson, Rohan, et al.
Publicado: (2016)

Animal models of heart failure with preserved ejection fraction
por: Conceição, G., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_oer85jajlttquha545838qm3ph